robaxin®/robaxin®-750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.
robaxin® and robaxin®-750 are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
Published Studies Related to Robaxin (Methocarbamol)
Bioequivalence study with two different oral formulations of methocarbamol in healthy subjects. A mono-centre, comparative, randomized, open-label, single-dose, 2-way crossover study. 
CONCLUSION: In this study bioequivalence could be demonstrated with respect to rate and extent of methocarbamol exposure.
Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. [1992.08]
The effects of orally administered placebo, diphenhydramine, lorazepam, methocarbamol and placebo were studied in volunteers with histories of recreational substance abuse including sedative/hypnotics. Placebo, diphenhydramine (100, 200 and 400 mg), lorazepam (1 and 4 mg) and methocarbamol (2.25 and 9 g) were tested in a randomized, double-blind crossover study using 14 subjects...
Antagonist effects of nalbuphine in opioid-dependent human volunteers. [1989.03]
The subjective, physiological and behavioral effects of nalbuphine, an opioid mixed agonist/antagonist analgesic, naloxone and hydromorphone were studied on adult, male, methadone-dependent volunteers living on a clinical research ward. The purpose was to assess nalbuphine's agonist properties vs.The withdrawal syndrome precipitated by nalbuphine was indistinguishable from that produced by naloxone.
A case report of unusual vasculitic reaction after Methocarbamol injection. 
Descriptive case report of a 42-year old woman with coetaneous vasculitis, and severe abdominal pain, which was led to diagnostic laparotomy... This case indicates, likely the potential for development of vasculitis with this medication.
Electrochemical determination of methocarbamol on a montmorillonite-Ca modified carbon paste electrode in formulation and human blood. [2010.10]
Utilizing the fascinating strong adsorptive ability, high chemical and mechanical stability properties of montmorillonite-calcium (MMT-Ca) clay, a MMT-Ca modified carbon paste electrode was developed for the sensitive determination of methocarbamol... Moreover, the developed method was successfully applied for determination of methocarbamol in human plasma of subjects following administration of an oral dose of Ibuflex tablets.
Clinical Trials Related to Robaxin (Methocarbamol)
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [Recruiting]
Different doses of relaxin will be compared to placebo to determine efficacy and safety for
the treatment of patients hospitalized with acute heart failure
A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure [Completed]
This trial is a single center, open-label, dose-finding study of recombinant human relaxin
(rhRlx) given intravenously (IV) to patients with stable, compensated CHF.
Recombinant Human Relaxin for the Treatment of Decompensated CHF [Active, not recruiting]
Two doses of relaxin will be compared to placebo for the treatment of patients with
Evaluation of the Safety of Relaxin in Preeclampsia [Recruiting]
The purpose of this study is to determine whether different doses of recombinant human
relaxin is safe when given to women with severe preeclampsia
Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor [Completed]
The purpose of this study is to assess the safety and efficacy of rhRlx for cervical
ripening, when compared to a placebo.
Reports of Suspected Robaxin (Methocarbamol) Side Effects
Mental Status Changes (6),
Condition Aggravated (4),
Medication Error (2),
Drug Dispensing Error (2),
Drug Hypersensitivity (2), more >>
Page last updated: 2011-12-09